Skip to main content

Table 1 Baseline characteristics

From: The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies

Number of patients 401
Age, years 59 (SE 0.6)
Female 76%
Disease duration, years 12 (SE 0.5)
DAS28-ESR at baseline 6.0 (SE 0.1)
RF-positive 81%
Anti-CCP-positive 81%
No previous biologicals 3%
One previous biological 47%
Two previous biologicals 34%
More than two previous biologicals 15%
  1. Anti-CCP, anti-cyclic citrullinated peptide antibody; DAS28, disease activity score using 28 joint counts; ESR, erythrocyte sedimentation rate; RF, rheumatoid factor; SE, standard error.